Exhibit 99.1 Intellia Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates CAMBRIDGE, Mass., Feb. 26, 2026 – Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today reported business updates and financial results for the fourth quarter and year ended December 31, 2025. "2025 was a time of accomplishment and resiliency for Intellia as we pres ...

Exhibit 99.1 Lantheus Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update BEDFORD, Mass., February 26, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (Lantheus or the Company) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today reported financial results for its fourth quarter and full year ended December 31, 2025. "In 2025 we accomplished the import ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K __________________ ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Registrant's telephone number, including area code: 416-504-0004 ____________________________ | Securities registered pursuant to Section 12(b) of the Act: | | | | --- | --- | --- | | Ti ...

Exhibit 99.1 Lindblad Expeditions Holdings, Inc. Reports 2025 Fourth Quarter and Full Year Financial Results 2025 Delivered the Strongest Adjusted EBITDA Performance in Company History Highlights: NEW YORK, February 26, 2026 – Lindblad Expeditions Holdings, Inc. (NASDAQ: LIND; the "Company" or "Lindblad"), a global provider of expedition cruises and adventure travel experiences, today reported financial results for the fourth quarter and full year ended December 31, 2025. Tour Revenues Full year tour revenu ...

INSTALLED BUILDING PRODUCTS REPORTS RECORD FOURTH QUARTER AND FISCAL YEAR 2025 PROFITABILITY Columbus, Ohio, February 26, 2026, Installed Building Products, Inc. (the "Company" or "IBP") (NYSE: IBP), an industry-leading installer of insulation and complementary building products, today announced results for the fourth quarter ended December 31, 2025. Fourth Quarter 2025 Highlights (Comparisons are to Prior Year Period) Recent Developments "We closed out 2025 with a strong fourth quarter performance deliveri ...

Exhibit 99.1 Eighth consecutive quarter of record net revenue in Israel, where PEACE NATURALS continues to be the number one cannabis brand ® 1 Industry leading balance sheet with $832 million in cash and cash equivalents and short-term investments TORONTO, February 26, 2026 - Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) ("Cronos" or the "Company"), today announced its 2025 fourth quarter and full-year business results. "Cronos delivered record net revenue, gross profit and Adjusted EBITDA in 2025, reflecti ...

Exhibit 99.1 NEW YORK – February 26, 2026 – Payoneer Global Inc. ("Payoneer" or the "Company") (NASDAQ: PAYO), the global financial technology company powering business growth across borders, today reported financial results for its fourth quarter and full year ended December 31, 2025. | | | | | | | YoY | | | YoY | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | ($ in mm unless otherwise noted) | 4Q 2024 | 1Q 2025 | 2Q 2025 | 3Q 2025 | 4Q 2025 | Change | 2024 | 2025 | Change | | Revenue ex. ...

Exhibit 99.1 Payoneer Reports Fourth Quarter and Full Year 2025 Financial Results 14% increase in revenue ex. interest, including 28% B2B revenue growth, in 2025 2026 Guidance reflects focus on high margin growth and significant core business profitability unlock NEW YORK – February 26, 2026 – Payoneer Global Inc. ("Payoneer" or the "Company") (NASDAQ: PAYO), the global financial technology company powering business growth across borders, today reported financial results for its fourth quarter and full year ...

(Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K AKEBIA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) 245 First Street, Cambridge, MA 02142 (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code: (6 ...

Table of Contents Collegium Pharmaceutical, Inc. (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37372 Virginia (State or other jurisdiction of ...